Di Paola Rossella, De Ananya, Capasso Anna, Giuliana Sofia, Ranieri Roberta, Ruosi Carolina, Sciarra Antonella, Vitagliano Caterina, Perna Alessandra F, Capasso Giovambattista, Simeoni Mariadelina
Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", 80138 Naples, Italy.
Department of Oncology, Livestrong Cancer Institutes, Dell Medical School, The University of Texas, Austin, TX 75063, USA.
J Pers Med. 2023 May 11;13(5):813. doi: 10.3390/jpm13050813.
Thyroid cancers require complex and heterogeneous therapies with different impacts on renal function. In our systematic literature review, we analyzed several aspects: renal function assessment, the impact of radiotherapy and thyroid surgery on kidney functioning, and mechanisms of nephrotoxicity of different chemotherapy, targeted and immunologic drugs. Our study revealed that the renal impact of thyroid cancer therapy can be a limiting factor in all radiotherapy, surgery, and pharmacological approaches. It is advisable to conduct a careful nephrological follow-up imposing the application of body surface based estimated Glomerular Filtration Rate (eGFR) formulas for the purpose of an early diagnosis and treatment of renal failure, guaranteeing the therapy continuation to thyroid cancer patients.
甲状腺癌需要采用复杂且具有异质性的治疗方法,这些方法对肾功能有不同影响。在我们的系统文献综述中,我们分析了几个方面:肾功能评估、放疗和甲状腺手术对肾脏功能的影响,以及不同化疗、靶向和免疫药物的肾毒性机制。我们的研究表明,甲状腺癌治疗对肾脏的影响可能是所有放疗、手术和药物治疗方法中的一个限制因素。建议进行仔细的肾脏随访,采用基于体表的估计肾小球滤过率(eGFR)公式,以便早期诊断和治疗肾衰竭,确保甲状腺癌患者能够持续接受治疗。